Author information from the last article
Avdeling for kreftbehandling
Oslo universitetssykehus
Forfatterbidrag: tolkning av data, litteratursøk, revisjon og godkjenning av manusrevisjoner.
Harald Holte er ph.d., overlege og tidligere leder av Norsk og Nordisk lymfomgruppe.
Articles by Harald Holte
Allogeneic stem cell transplantation for patients with lymphoma 2011–21
- Hege Melby Frøen,
- Marianne Brodtkorb,
- Harald Holte,
- Arne Kolstad,
- Anders Eivind Myhre,
- Mats Remberger,
- Geir Erland Tjønnfjord,
- Tobias Gedde-Dahl
03.03.2025:
Allogeneic stem cell transplantation (ASCT) is potentially curative for patients with haematologic malignancies, lymphomas and certain non-malignant conditions. However, it carries a risk of severe complications and transplant-related mortality due to organ damage, infection and graft-versus-host...
High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Alexander Fosså,
- Jens Hammerstrøm,
- Vidar Jetne,
- Arne Kolstad,
- Gunnar Kvalheim,
- Jon Håvard Loge,
- Turid Løkeland,
- Jon Magnus Tangen,
- Harald Holte,
- Stein Kvaløy
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) for lymphomas has been given in Norway since 1987. The therapy consists of intensive chemotherapy and/or total body irradiation in such high doses that it entails a life-threatening loss of healthy haematopoietic stem cells in the bone marrow...
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987 – 2008
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Anne Kirsti Blystad,
- Unn Merete Fagerli,
- Øystein Fluge,
- Alexander Fosså,
- Jens Hammerstrøm,
- Arne Kolstad,
- Jon Håvard Loge,
- Martin Maisenhølder,
- Bjørn Østenstad,
- Stein Kvaløy,
- Harald Holte
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) is a very intensive, highly specialised and resource-intensive therapy. It has been a treatment option for lymphomas for 25 years. Based on results from prospective studies, it has progressed from being an experimental form of treatment to...